Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Sodium with Chemotherapy in Extensive Stage SCLC
NCT00916669Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2008
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of enoxaparin in small cell lung cancer (SCLC), sponsored by Massachusetts General Hospital. Planned start Jul 2008; status: withdrawn.
02
Drugs
enoxaparin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00916669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00916669.